• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非肥胖型非酒精性脂肪性肝病患者中与显著肝纤维化相关的肠道微生物组和代谢物的独特特征。

Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.

机构信息

Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, 08826, Republic of Korea.

Institute of Health and Environment, Seoul National University, Seoul, 08826, Republic of Korea.

出版信息

Nat Commun. 2020 Oct 5;11(1):4982. doi: 10.1038/s41467-020-18754-5.

DOI:10.1038/s41467-020-18754-5
PMID:33020474
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7536225/
Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity but also found in non-obese individuals. Gut microbiome profiles of 171 Asians with biopsy-proven NAFLD and 31 non-NAFLD controls are analyzed using 16S rRNA sequencing; an independent Western cohort is used for external validation. Subjects are classified into three subgroups according to histological spectra of NAFLD or fibrosis severity. Significant alterations in microbiome diversity are observed according to fibrosis severity in non-obese, but not obese, subjects. Ruminococcaceae and Veillonellaceae are the main microbiota associated with fibrosis severity in non-obese subjects. Furthermore, stool bile acids and propionate are elevated, especially in non-obese subjects with significant fibrosis. Fibrosis-related Ruminococcaceae and Veillonellaceae species undergo metagenome sequencing, and four representative species are administered in three mouse NAFLD models to evaluate their effects on liver damage. This study provides the evidence for the role of the microbiome in the liver fibrosis pathogenesis, especially in non-obese subjects.

摘要

非酒精性脂肪性肝病 (NAFLD) 与肥胖有关,但也存在于非肥胖个体中。通过 16S rRNA 测序分析了 171 名经活检证实的 NAFLD 亚洲患者和 31 名非 NAFLD 对照组的肠道微生物组谱;一个独立的西方队列用于外部验证。根据 NAFLD 的组织学谱或纤维化严重程度,将受试者分为三个亚组。在非肥胖受试者中,根据纤维化严重程度观察到微生物组多样性的显著改变,但在肥胖受试者中则没有。在非肥胖受试者中,瘤胃球菌科和韦荣氏球菌科是与纤维化严重程度相关的主要微生物群。此外,粪便胆汁酸和丙酸盐水平升高,尤其是在非肥胖且存在显著纤维化的受试者中。对与纤维化相关的瘤胃球菌科和韦荣氏球菌科物种进行宏基因组测序,并在三种小鼠 NAFLD 模型中给予四种代表性物种,以评估它们对肝损伤的影响。本研究为微生物组在肝纤维化发病机制中的作用提供了证据,尤其是在非肥胖受试者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/c01dc720ab0c/41467_2020_18754_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/05b17cce6b57/41467_2020_18754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/cdc7cf225c57/41467_2020_18754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/203082264578/41467_2020_18754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/a2d8a4f33f4a/41467_2020_18754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/336ca4cd11eb/41467_2020_18754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/28cfed0d2369/41467_2020_18754_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/f737e4574f49/41467_2020_18754_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/c01dc720ab0c/41467_2020_18754_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/05b17cce6b57/41467_2020_18754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/cdc7cf225c57/41467_2020_18754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/203082264578/41467_2020_18754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/a2d8a4f33f4a/41467_2020_18754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/336ca4cd11eb/41467_2020_18754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/28cfed0d2369/41467_2020_18754_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/f737e4574f49/41467_2020_18754_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4644/7536225/c01dc720ab0c/41467_2020_18754_Fig8_HTML.jpg

相似文献

1
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.非肥胖型非酒精性脂肪性肝病患者中与显著肝纤维化相关的肠道微生物组和代谢物的独特特征。
Nat Commun. 2020 Oct 5;11(1):4982. doi: 10.1038/s41467-020-18754-5.
2
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
3
Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation.单核细胞-巨噬细胞激活与 HIV 单核感染相关的非酒精性脂肪性肝病和肝纤维化有关,而与肠道微生物组和细菌易位无关。
AIDS. 2019 Apr 1;33(5):805-814. doi: 10.1097/QAD.0000000000002133.
4
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.非酒精性脂肪性肝病的严重程度与肠道菌群失调及肠道微生物群代谢功能的改变有关。
Hepatology. 2016 Mar;63(3):764-75. doi: 10.1002/hep.28356. Epub 2016 Jan 13.
5
Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids.肠道微生物群的调节影响非酒精性脂肪性肝病:胆汁酸的潜在作用。
J Lipid Res. 2017 Jul;58(7):1399-1416. doi: 10.1194/jlr.M075713. Epub 2017 May 22.
6
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.
7
Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.肥胖与非肥胖受试者粪便和血液微生物群特征及非酒精性脂肪性肝病的存在。
PLoS One. 2019 Mar 14;14(3):e0213692. doi: 10.1371/journal.pone.0213692. eCollection 2019.
8
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝炎发生过程中肠道微生物组和代谢组的动态变化。
World J Gastroenterol. 2018 Jun 21;24(23):2468-2481. doi: 10.3748/wjg.v24.i23.2468.
9
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.非酒精性脂肪性肝炎(NASH)瘦患者的肠道微生物群组成与肝损伤相关,且独立于热量摄入:一项前瞻性试点研究。
Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384. doi: 10.1016/j.numecd.2017.10.014. Epub 2017 Oct 26.
10
The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD.肥胖母亲的婴儿肠道微生物群会增加炎症反应和非酒精性脂肪性肝病易感性。
Nat Commun. 2018 Oct 26;9(1):4462. doi: 10.1038/s41467-018-06929-0.

引用本文的文献

1
Endogenous Ethanol Metabolism and Development of MASLD-MASH.内源性乙醇代谢与代谢相关脂肪性肝病-脂肪性肝炎的发展
Int J Mol Sci. 2025 Sep 4;26(17):8609. doi: 10.3390/ijms26178609.
2
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
3
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value.

本文引用的文献

1
Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation.肠道菌群失调导致的次级胆汁酸缺乏会促进肠道炎症。
Cell Host Microbe. 2020 Apr 8;27(4):659-670.e5. doi: 10.1016/j.chom.2020.01.021. Epub 2020 Feb 25.
2
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
3
Species-level functional profiling of metagenomes and metatranscriptomes.宏基因组和宏转录组的物种水平功能分析。
代谢功能障碍相关脂肪性肝病中的肠道微生物群与代谢组学:相互作用、机制及治疗价值
Front Cell Infect Microbiol. 2025 Jul 23;15:1635638. doi: 10.3389/fcimb.2025.1635638. eCollection 2025.
4
Role of NLRP3 in the metabolism of bile acids and gut microbiota in CCl4-induced liver fibrosis.NLRP3在四氯化碳诱导的肝纤维化中胆汁酸代谢和肠道微生物群中的作用。
Microbiol Spectr. 2025 Jul 21:e0014825. doi: 10.1128/spectrum.00148-25.
5
Inflammation in MASLD progression and cancer.非酒精性脂肪性肝病进展与癌症中的炎症
JHEP Rep. 2025 Apr 2;7(8):101414. doi: 10.1016/j.jhepr.2025.101414. eCollection 2025 Aug.
6
A specifically designed multi-biotic reduces uremic toxin generation and improves kidney function.一种专门设计的多种生物制剂可减少尿毒症毒素的产生并改善肾功能。
Gut Microbes. 2025 Dec;17(1):2531202. doi: 10.1080/19490976.2025.2531202. Epub 2025 Jul 12.
7
Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.代谢功能障碍相关脂肪性肝病及相关肝细胞癌中的肠道微生物群
Nat Rev Gastroenterol Hepatol. 2025 Jul 7. doi: 10.1038/s41575-025-01089-1.
8
Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.瘦素状态对非酒精性脂肪性肝病(NAFLD)患者死亡率的影响:一项系统评价和荟萃分析。
Pak J Med Sci. 2025 Jun;41(6):1845-1853. doi: 10.12669/pjms.41.6.12044.
9
Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.肝硬化合并门静脉血栓形成患者肠道及循环微生物群特征分析
Front Microbiol. 2025 Jun 19;16:1597145. doi: 10.3389/fmicb.2025.1597145. eCollection 2025.
10
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
Nat Methods. 2018 Nov;15(11):962-968. doi: 10.1038/s41592-018-0176-y. Epub 2018 Oct 30.
4
Regional variation limits applications of healthy gut microbiome reference ranges and disease models.区域差异限制了健康肠道微生物群参考范围和疾病模型的应用。
Nat Med. 2018 Oct;24(10):1532-1535. doi: 10.1038/s41591-018-0164-x. Epub 2018 Aug 27.
5
Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study.非酒精性脂肪性肝炎(NASH)瘦患者的肠道微生物群组成与肝损伤相关,且独立于热量摄入:一项前瞻性试点研究。
Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384. doi: 10.1016/j.numecd.2017.10.014. Epub 2017 Oct 26.
6
Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.载脂蛋白基因 PNPLA3 和 TM6SF2 对非酒精性脂肪性肝病组织学严重程度的影响。
J Gastroenterol Hepatol. 2018 Jun;33(6):1277-1285. doi: 10.1111/jgh.14056. Epub 2018 Feb 26.
7
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.非酒精性脂肪性肝病患者尽管初级和次级胆汁酸产生增加,但肝胆汁酸信号受到抑制。
Gut. 2018 Oct;67(10):1881-1891. doi: 10.1136/gutjnl-2017-314307. Epub 2017 Aug 3.
8
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.二甲双胍改变了未经治疗的 2 型糖尿病患者的肠道微生物组,从而促进了药物的治疗效果。
Nat Med. 2017 Jul;23(7):850-858. doi: 10.1038/nm.4345. Epub 2017 May 22.
9
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.基于肠道微生物群的宏基因组特征用于非侵入性检测人类非酒精性脂肪性肝病中的晚期纤维化
Cell Metab. 2017 May 2;25(5):1054-1062.e5. doi: 10.1016/j.cmet.2017.04.001.
10
Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice.普拉梭菌治疗可改善高脂喂养小鼠的肝脏健康并减轻脂肪组织炎症。
ISME J. 2017 Jul;11(7):1667-1679. doi: 10.1038/ismej.2017.24. Epub 2017 Apr 4.